UiPath Pivots to Healthcare: New AI Agents Debut as Wall Street Stays in Wait-and-See Mode

In a bid to shed its reputation as a "legacy" automation vendor, UiPath ($PATH) has officially entered the high-stakes world of specialized healthcare AI. The expansion, unveiled at the ViVE 2026 conference in late February, represents a strategic move toward "Agentic AI"—tools that don't just follow instructions but autonomously manage complex medical and financial workflows.Despite this aggressive technological pivot and a recent string of earnings beats, the company’s valuation continues to sit in a stubborn "trough," trailing far behind the bullish price targets set by Wall Street analysts.1. The Healthcare "Agent" OffensiveUiPath is moving past simple data scraping and into the "cognitive" heavy lifting of hospital administration. The new suite of Agentic AI solutions is specifically designed to bridge the gap between fragmented clinical records and the rigid data requirements of insurance payers.Medical Records Summarization (MRS): This tool converts massive, unorganized patient files into source-certified summaries. Early data shows a staggering 90% reduction in clinician review time, dropping from an average of 70 minutes to just 6 minutes per case.Claim Denial Prevention: Leveraging the acquisition of WorkFusion, this agent identifies the root causes of medical claim denials before they happen, orchestrating corrective actions and appeals to protect hospital revenue.Prior Authorization: In partnership with Genzeon, UiPath now offers an agent that verifies benefits and matches clinical data to medical-necessity rules in real-time.2. The Genzeon Partnership: A Regulatory MoatTo navigate the complex legal landscape of healthcare, UiPath has teamed up with Genzeon, a firm recognized by the U.S. Department of Health and Human Services (CMS).Strategic Credibility: Genzeon’s presence in the WISeR (Wasteful and Inappropriate Services Reduction) model gives UiPath immediate access to an audit-ready compliance framework.Deep Domain Expertise: This isn't just "general" AI; it uses over 30 disease-specific clinical models to ensure that the automation understands the actual medicine behind the paperwork.3. Valuation Disconnect: The "Hold" ConsensusWhile the technology is advancing, UiPath’s stock is telling a different story. As of early March 2026, the shares are trading around $11.80, nearly 40% below their 52-week high of $19.84.The Target Gap: The average analyst price target stands at approximately $15.93, with some firms like Evercore and Barclays reaching as high as $17.00–$19.00. This implies a potential upside of over 35%, yet most analysts (roughly 85%) maintain a "Hold" rating.The "SaaS Transition" Friction: Investors remain cautious about the company’s transition to a SaaS model, which has caused a temporary "dip" in Net Revenue Retention (falling to 107% from 113% last year).Valuation Multiples: Interestingly, UiPath is trading at a Forward P/E of roughly 15.11, significantly lower than the software industry average of 20.44, suggesting the market has not yet "re-rated" the stock to reflect its new AI capabilities.4. What’s Next: The March 11 CatalystAll eyes are now on the upcoming Q4 2026 earnings report scheduled for March 11, 2026.Earnings Expectations: Analysts are looking for an EPS of $0.25 and revenue of roughly $464 million.Management Integrity: Following recent modest share sales by CEO Daniel Dines and CFO Ashim Gupta, investors are looking for a "conviction signal" from management that the healthcare push is translating into accelerated Annual Recurring Revenue (ARR).Analyst View: "UiPath is doing exactly what it needs to do technologically—moving from horizontal RPA to vertical AI agents. However, until we see these healthcare contracts move the needle on the bottom line, the market is treating this as a 'show me' story."